ArticleInternational journal of clinical and experimental pathology2015
Enhanced circulating ILC2s accompany by upregulated MDSCs in patients with asthma.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- Article
- Butyrate inhibits iILC2-mediated lung inflammation via lung-gut axis in chronic obstructive pulmonary disease (COPD).BMC pulmonary medicine · 2023Article
- MDSCs Aggravate the Asthmatic Progression in Children and OVA-Allergic Mice by Regulating the Th1/Th2/Th17 Responses.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Role of Chemokines and Inflammatory Cells in Respiratory Allergy.Journal of asthma and allergy · 2022Review
- Group 2 Innate Lymphoid Cells in Human Respiratory Disorders.Journal of innate immunity · 2020Review
- Regulation of Human Innate Lymphoid Cells in the Context of Mucosal Inflammation.Frontiers in immunology · 2020Review
- The Key Role of TNF-TNFR2 Interactions in the Modulation of Allergic Inflammation: A Review.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Group 2 innate lymphoid cells (ILC2s) are considered to be the most significant mediators during the orchestration of immune responses in asthma. Myeloid-derived suppressor cells (MDSCs) has received a great deal of attention for their immunosuppressive activity, and our early studies indicate that the increased Th2 cytokines are associated with MDSCs. In this study, we sought to determine whether MDSCs are also participation in immune imbalance and its relationship with ILC2s in asthma. The data showed that the circulatory ILC2s or MDSCs and their characteristic cytokines or transcription factors were significantly enhanced in asthmatic patients, as well as in chronic obstructive pulmonary disease (COPD) or respiratory viral infections (RVI). Meanwhile, a Th2-dominated phenotype was found in patients with asthma which closely related to the expression levels of ILC2s and MDSCs associated moleculars. These findings indicated that Th2 polarization was close related to synergistically increased ILC2s and MDSCs, it may allow to further the comprehension of the contribution of these cells to the inflammatory response involved in asthma or other respiratory tract inflammatory diseases, such as COPD and RVI, as well as to develop novel therapeutic strategies.
Indexed as
Identifiers
26097539PMC4466926W2464792235What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.